Chai Discovery
Chai is a research lab working on AI to unlock biology. Our models design new molecules for new medicines. We are changing how biologists develop drugs, just as language models are changing how engineers write code.
CORE INFO
Chai Discovery is a biotechnology company that leverages artificial intelligence to enhance drug discovery processes, enabling pharmaceutical researchers to design and evaluate new molecules more efficiently. Their AI-driven platforms, such as Chai-1 and Chai-2, are particularly beneficial for pharmaceutical teams aiming to target areas that traditional methods have struggled to address.
- Chai Discovery raised $130 million in a Series B funding round in December 2025, led by General Catalyst and Oak HC/FT, reaching a valuation of $1.3 billion.bloomberg.com
- The company has established partnerships with major pharmaceutical companies, including Eli Lilly and Pfizer, to deploy their AI models and accelerate drug discovery efforts.linkedin.com
- Chai Discovery was recognized in Forbes' AI 50 list in 2026, highlighting its prominence in the AI-driven biotech sector.forbes.com
WHY WE WOULD WORK AT CHAI DISCOVERY
Revolutionary Mission
Join a team dedicated to transforming drug discovery by treating biology as an engineering discipline, enhancing the precision and speed of new medicine design.
Cutting-Edge Technology
Work with advanced AI-driven platforms like Chai-1 and Chai-2, designed to predict molecular interactions and accelerate therapeutic development.
Collaborative Culture
Be part of a small, dynamic team of innovators where collaboration and creativity drive the development of groundbreaking solutions in biotech.
Strong Funding Backing
Benefit from significant financial support, including a recent $130 million Series B funding round, ensuring stability and resources for ambitious projects.
Notable Partnerships
Contribute to impactful projects with major pharmaceutical companies like Eli Lilly and Pfizer, enhancing drug discovery efforts that can change lives.
Innovative Work Environment
Experience a culture that fosters innovation and encourages the exploration of new ideas, making a real difference in the biotech landscape.
MARKET AND TRACTION
TOTAL FUNDING
✦ KEY METRICNOTABLE CUSTOMERS
KEY METRICS
✦ KEY METRICGROWTH TACTICS
MARKET POSITION
PRODUCT AND TECH
Chai-1 Platform
Chai-1 is an AI-driven platform designed for molecular structure prediction, enabling researchers to efficiently generate and assess novel molecules based on specific target inputs, significantly reducing the need for extensive empirical screening.
Chai-2 Platform
Chai-2 focuses on antibody design, leveraging advanced AI models to enhance the precision and success rates of antibody development, thereby accelerating the therapeutic discovery process.
AI-Driven Drug Discovery
Chai Discovery employs artificial intelligence to predict and reprogram biochemical molecule interactions, transforming traditional drug discovery methods and enabling pharmaceutical teams to target previously challenging areas.
Engineering Biology Approach
The company's mission is to treat biology as an engineering discipline, which enhances the speed and precision of new medicine design, ultimately revolutionizing therapeutic development workflows.
Partnerships with Pharma
Chai Discovery has established strategic partnerships with major pharmaceutical companies like Eli Lilly and Pfizer, facilitating the deployment of their AI models to accelerate drug discovery efforts.